Vir Biotechnology Inc.’s acquisition of Humabs BioMed SA

The owners of Humabs BioMed SA, a Swiss biotechnology firm located in Bellinzona and focused on discovering and developing fully human monoclonal antibodies to treat serious infections with a unique proprietary discovery technology, sold their interests to Vir Biotechnology Inc.

Vir Biotechnology is founded by ARCH Venture Partners and seeded by ARCH, the Bill & Melinda Gates Foundation, Altitude Life Science Ventures, Alta Partners and further investors. They aim at creating a global platform to transform the care of people with serious infectious diseases.

Humabs and its employees will continue to operate the Humabs facilities in Bellinzona, Switzerland and maintain its productive research collaboration with the Institute for Research in Biomedicine.

Bär & Karrer acted as legal advisor of the sellers on the deal with a team included Paolo Bottini (picture), Edoardo Buzzi and Paolo Ader (all M&A) and Markus Wang (IP).

Involved fees earner: Paolo Bottini – Bär & Karrer; Edoardo Buzzi – Bär & Karrer; Paolo Ader – Bär & Karrer; Markus Wang – Bär & Karrer;

Law Firms: Bär & Karrer;

Clients: Humabs BioMed SA;